BRAF and central nervous system neoplasm: Although encorafenib features a longer dissociation half-life from BRAF V600E and potentially better pharmacodynamic suppression of MAPK signaling, its efficacy in CNS tumors may be limited by its lower BBB penetration (Table 1) [90].